Technical Analysis for GRTS - Gritstone Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.58 | -6.13% | -0.04 |
GRTS closed down 6.13 percent on Monday, July 1, 2024, on 1.32 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -6.13% | |
| New 52 Week Closing Low | Bearish | -6.13% | |
| Expansion Breakdown | Bearish Swing Setup | -6.13% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 8 hours ago |
| Down 5% | about 8 hours ago |
| Down 3% | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| Down 1% | about 9 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.33 |
| 52 Week Low | 0.578 |
| Average Volume | 2,009,845 |
| 200-Day Moving Average | 1.67 |
| 50-Day Moving Average | 0.79 |
| 20-Day Moving Average | 0.74 |
| 10-Day Moving Average | 0.71 |
| Average True Range | 0.06 |
| RSI (14) | 28.57 |
| ADX | 24.78 |
| +DI | 10.83 |
| -DI | 30.53 |
| Chandelier Exit (Long, 3 ATRs) | 0.64 |
| Chandelier Exit (Short, 3 ATRs) | 0.77 |
| Upper Bollinger Bands | 0.85 |
| Lower Bollinger Band | 0.63 |
| Percent B (%b) | -0.2 |
| BandWidth | 30.00 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0089 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.68 | ||||
| Resistance 3 (R3) | 0.69 | 0.67 | 0.66 | ||
| Resistance 2 (R2) | 0.67 | 0.64 | 0.66 | 0.66 | |
| Resistance 1 (R1) | 0.62 | 0.63 | 0.61 | 0.61 | 0.65 |
| Pivot Point | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 |
| Support 1 (S1) | 0.56 | 0.58 | 0.55 | 0.55 | 0.51 |
| Support 2 (S2) | 0.53 | 0.56 | 0.53 | 0.50 | |
| Support 3 (S3) | 0.49 | 0.53 | 0.50 | ||
| Support 4 (S4) | 0.48 |
